Repository logo
Log in(current)
Repository logoMIT Open ScholarshipDSpace@MIT
  1. Home
  2. MIT Open Access Articles
  3. MIT Open Access Articles
  4. Small molecule inhibition of apicomplexan FtsH1 disrupts plastid biogenesis in human pathogens

Small molecule inhibition of apicomplexan FtsH1 disrupts plastid biogenesis in human pathogens

Thumbnail Image
Download
Name

elife-29865-v2.pdf

Size

848.25 KB

Format

Adobe PDF

Checksum (MD5)

d442b31703d887ba1c51f5e826c021b2

Download all files submitted through automated deposit
sword-2018-02-02.original.zip (630.12 KB)
Author(s)
Amberg-Johnson, Katherine
•
Ganesan, Suresh M.
•
Lorenzi, Hernan A.
•
Niles, Jacquin C.
•
Yeh, Ellen
•
Hari, Sanjay B.
•
Sauer, Robert T.
Date Issued
August 2017
Journal
eLife
Publisher
eLife Sciences Publications, Ltd
Citation
Amberg-Johnson,et al. “Small Molecule Inhibition of Apicomplexan FtsH1 Disrupts Plastid Biogenesis in Human Pathogens.” eLife 2017, 6 (August 2017): e29865 © Amberg-Johnson et al
Version
Final published version
Abstract
The malaria parasite Plasmodium falciparum and related apicomplexan pathogens contain an essential plastid organelle, the apicoplast, which is a key anti-parasitic target. Derived from secondary endosymbiosis, the apicoplast depends on novel, but largely cryptic, mechanisms for protein/lipid import and organelle inheritance during parasite replication. These critical biogenesis pathways present untapped opportunities to discover new parasite-specific drug targets. We used an innovative screen to identify actinonin as having a novel mechanism-of-action inhibiting apicoplast biogenesis. Resistant mutation, chemical-genetic interaction, and biochemical inhibition demonstrate that the unexpected target of actinonin in P. falciparum and Toxoplasma gondii is FtsH1, a homolog of a bacterial membrane AAA+ metalloprotease. PfFtsH1 is the first novel factor required for apicoplast biogenesis identified in a phenotypic screen. Our findings demonstrate that FtsH1 is a novel and, importantly, druggable antimalarial target. Development of FtsH1 inhibitors will have significant advantages with improved drug kinetics and multistage efficacy against multiple human parasites.
MIT Department
Massachusetts Institute of Technology. Department of Biological Engineering
Massachusetts Institute of Technology. Department of Biology
Terms of Use
Creative Commons Attribution 4.0 International License
https://creativecommons.org/licenses/by/4.0/
Persistent DSpace Link
http://hdl.handle.net/1721.1/113561
DOI of Published Version
https://doi.org/10.7554/ELIFE.29865
Repository logo
PrivacyPermissionsAccessibilityContact us
Repository logo
Notify us about copyright concerns.